Citations

Mayo Clinic

Showing 10 of 108523 citations.

Enhanced Pulmonary Vasodilator Reserve and Abnormal Right Ventricular
Andersen, Mads J. , Hwang, Seok-Jae, Kane, Garvan C. , Melenovský, Vojtěch , Olson, Thomas P. , Fetterly, Kenneth A. , Borlaug, Barry A. , Fetterly, Kenneth, Hwang, Seok‐Jae , Borlaug, Barry A , Melenovský, Vojtěch , Andersen, Mads Jønsson

Circulation: Heart Failure | April 10, 2015 | Volume: 8 | Issue: 3 | Pages: 542-550

10.1161/circheartfailure.114.002114 | PMID 25857307 Get It

Background— Pulmonary hypertension and right ventricular (RV) dysfunction are common in patients with advanced heart failure with preserved ejection fraction (HFpEF), yet their underlying mechanisms remain poorly understood. We sought to examine RV–pulmonary artery (PA) functional reserve responses and RV–PA coupling at rest and during β-adrenergic stimulation in subjects with earlier stage HFpEF. Methods and Results— In a prospective trial, subjects with HFpEF (n=39) and controls (n=18) underwent comprehensive invasive and noninvasive hemodynamic assessment using high fidelity micromanometer catheters, echocardiography, and expired gas analysis at rest and during dobutamine infusion. HFpEF subjects displayed similar RV structure but significantly impaired RV systolic (lower RV d P /d t max /IP and s′) and diastolic function (higher RV τ) coupled with more severe pulmonary vascular disease, manifest by higher PA pressures, higher PA resistance, and lower PA compliance compared with controls. Dobutamine infusion caused greater pulmonary vasodilation in HFpEF compared with controls, with enhanced reductions in PA resistance, greater increase in PA compliance, and a more negative slope in the PA pressure–flow relationship when compared with controls (all P <0.001). RV–PA coupling analysis revealed that dobutamine improved RV ejection in HFpEF subjects through afterload reduction alone, rather than through enhanced contractility, indicating RV systolic reserve dysfunction. Conclusions— Pulmonary hypertension in early stage HFpEF is related to partially reversible pulmonary vasoconstriction coupled with RV systolic and diastolic dysfunction, even in the absence of RV structural remodeling. Pulmonary vascular tone is more favorably responsive to β-adrenergic stimulation in HFpEF than controls, suggesting a potential role for β-agonists in the treatment of patients with HFpEF and pulmonary hypertension. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01418248.
Early CNS neurodegeneration in radiologically isolated syndrome
Azevedo, Christina , Overton, Eve , Khadka, Sankalpa, Buckley, Jessica, Sampat, Mehul, Kantarci, Orhun H. , Lebrun‐Frénay, Christine , Sıva, Aksel , Okuda, Darin T. , Pelletier, Daniel , Azevedo, Christina J, Liu, Shuang , Lebrun Frenay, Christine, Liu, Shuang , Lebrun‐Frénay, Christine , Siva, Aksel , Okuda, Darin T

Neurology Neuroimmunology & Neuroinflammation | April 10, 2015 | Volume: 2 | Issue: 3 | Pages: No page available

10.1212/nxi.0000000000000102 | PMID 25884012 Get It

MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease
Dulai, Parambir S. , Singh, Siddharth , Cesarini, Monica , Nelson, Sigrid, Feagan, Brian G. , Ordás, Íngrid , Sandborn, William J. , Santillan, Cynthia , D’Haens, Geert , Stoker, Jaap , MacDonald, John K, Levesque, Barrett G., Bouguen, Guillaume , Peyrin‐Biroulet, Laurent , Rimola, Jordi , Panés, Julián , Zou, Guangyong , Stoker, Jaap , Ordás, Ingrid

Cochrane Database of Systematic Reviews | April 10, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd011630 Get It

RETRACTED: Development of an Experimental Animal Model for Lower Back Pain by Percutaneous Injury‐Induced Lumbar Facet Joint Osteoarthritis
Ahmadinia, Kasra, Hamilton, John L. , Andrews, Steven W., Haralampus, Chris A., Xiao, Guozhi , Sohn, Hong‐Moon, You, Jae‐Won, Seo, Yo‐Seob, Stein, Gary S., Wijnen, André J. van , Kim, Su‐Gwan, Im, Hee‐Jeong, van Wijnen, Andre J, Kim, Jae‐Sung , Li, Xin , Sohn, Hong Moon , You, Jae Won , Im, Hee‐Jeong , van Wijnen, Andre J , Hamilton, John

Journal of Cellular Physiology | April 9, 2015 | Volume: 230 | Issue: 11 | Pages: 2837-2847

10.1002/jcp.25015 | PMID 25858171 Get It

We report generation and characterization of pain‐related behavior in a minimally invasive facet joint degeneration (FJD) animal model in rats. FJD was produced by a non‐open percutaneous puncture‐induced injury on the right lumbar FJs at three consecutive levels. Pressure hyperalgesia in the lower back was assessed by measuring the vocalization response to pressure from a force transducer. After hyperalgesia was established, pathological changes in lumbar FJs and alterations of intervertebral foramen size were assessed by histological and imaging analyses. To investigate treatment options for lumber FJ osteoarthritis‐induced pain, animals with established hyperalgesia were administered with analgesic drugs, such as morphine, a selective COX‐2 inhibitor, a non‐steroidal anti‐inflammatory drug (NSAID) (ketorolac), or pregabalin. Effects were assessed by behavioral pain responses. One week after percutaneous puncture‐induced injury of the lumbar FJs, ipsilateral primary pressure hyperalgesia developed and was maintained for at least 12 weeks without foraminal stenosis. Animals showed decreased spontaneous activity, but no secondary hyperalgesia in the hind paws. Histopathological and microfocus X‐ray computed tomography analyses demonstrated that the percutaneous puncture injury resulted in osteoarthritis‐like structural changes in the FJs cartilage and subchondral bone. Pressure hyperalgesia was completely reversed by morphine. The administration of celecoxib produced moderate pain reduction with no statistical significance while the administration of ketorolac and pregabalin produced no analgesic effect on FJ osteoarthritis‐induced back pain. Our animal model of non‐open percutanous puncture‐induced injury of the lumbar FJs in rats shows similar characteristics of low back pain produced by human facet arthropathy. J. Cell. Physiol. 9999: 2837–2847, 2015. © 2015 Wiley Periodicals, Inc.
New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton
Khosla, Sundeep , Khosla, Sundeep

Journal of Bone and Mineral Research | April 9, 2015 | Volume: 30 | Issue: 7 | Pages: 1134-1137

10.1002/jbmr.2529 | PMID 25857392 Get It

Estrogens and Their Genotoxic Metabolites Are Increased in Obese Prepubertal Girls
Mauras, Nelly , Santen, Richard J. , Colón‐Otero, Gerardo , Hossain, Jobayer , Wang, Qingqing , Mesaros, Clementina , Blair, Ian A, Blair, Ian A.

The Journal of Clinical Endocrinology & Metabolism | April 9, 2015 | Volume: 100 | Issue: 6 | Pages: 2322-2328

10.1210/jc.2015-1495 | PMID 25856214 Get It

Macro-Quest
Rajkumar, S. Vincent , Rajkumar, S Vincent

Blood | April 9, 2015 | Volume: 125 | Issue: 15 | Pages: 2318-2319

10.1182/blood-2015-02-628404 | PMID 25858889 Get It

Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population‐based study
Leibson, Cynthia L., Long, Kirsten Hall , Ransom, Jeanine E. , Roberts, Rosebud O., Hass, Steven , Duhig, Amy, Smith, Carin Y. , Emerson, Jane A., Petersen, Ronald C. , Pankratz, V. Shane , Smith, Carin Y

Alzheimer's & Dementia | April 9, 2015 | Volume: 11 | Issue: 8 | Pages: 917-932

10.1016/j.jalz.2015.01.007 | PMID 25858682 Get It

Abstract Background Objective cost estimates and source of cost differences are needed across the spectrum of cognition, including cognitively normal (CN), mild cognitive impairment (MCI), newly discovered dementia, and prevalent dementia. Methods Subjects were a subset of the Mayo Clinic Study of Aging stratified‐random sampling of Olmsted County, MN, residents aged 70 to 89 years. A neurologist reviewed provider‐linked medical records to identify prevalent dementia (review date = index). Remaining subjects were invited to participate in prospective clinical/neuropsychological assessments; participants were categorized as CN, MCI, or newly discovered dementia (assessment date = index). Costs for medical services/procedures 1‐year pre‐index (excluding indirect and long‐term care costs) were estimated using line‐item provider‐linked administrative data. We estimated contributions of care‐delivery site and comorbid conditions (including and excluding neuropsychiatric diagnoses) to between‐category cost differences. Results Annual mean medical costs for CN, MCI, newly discovered dementia, and prevalent dementia were $6042, $6784, $9431, $11,678, respectively. Hospital inpatient costs contributed 70% of total costs for prevalent dementia and accounted for differences between CN and both prevalent and newly discovered dementia. Ambulatory costs accounted for differences between CN and MCI. Age‐, sex‐, education‐adjusted differences reached significance for CN versus newly discovered and prevalent dementia and for MCI versus prevalent dementia. After considering all comorbid diagnoses, between‐category differences were reduced (e.g., prevalent dementia minus MCI (from $4842 to $3575); newly discovered dementia minus CN (from $3578 to $711)). Following the exclusion of neuropsychiatric diagnoses from comorbidity adjustment, between‐category differences tended to revert to greater differences. Conclusions Cost estimates did not differ significantly between CN and MCI. Substantial differences between MCI and prevalent dementia reflected high inpatient costs for dementia and appear partly related to co‐occurring mental disorders. Such comparisons can help inform models aimed at identifying where, when, and for which individuals proposed interventions might be cost‐effective.
Performance of the CogState computerized battery in the Mayo Clinic Study on Aging
Mielke, Michelle M. , Hagen, Clinton E., Edwards, Kelly K., Roberts, Rosebud O., Jack, Clifford R. , Petersen, Ronald C. , Machulda, Mary M. , Pankratz, V. Shane , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M

Alzheimer's & Dementia | April 9, 2015 | Volume: 11 | Issue: 11 | Pages: 1367-1376

10.1016/j.jalz.2015.01.008 | PMID 25858683 Get It

AbstractIntroductionThe feasibility and validity of brief computerized cognitive batteries at the population‐level are unknown.MethodsNondemented participants (n = 1660, age 50–97 years) in the Mayo Clinic Study on Aging completed the computerized CogState battery and standard neuropsychological battery. The correlation between tests was examined and comparisons between CogState performance on the personal computer (PC) and iPad (n = 331), and in the clinic vs. at home (n = 194), were assessed.ResultsWe obtained valid data on greater than 97% of participants on each test. Correlations between the CogState and neuropsychological tests ranged from −0.462 to 0.531. Although absolute differences between the PC and iPad were small and participants preferred the iPad, performance on the PC was faster. Participants performed faster on Detection, One Card Learning, and One Back at home compared with the clinic.DiscussionThe computerized CogState battery, especially the iPad, was feasible, acceptable, and valid in the population.
Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b‐AP15
D’Arcy, Pádraig , Caulfield, Thomas R. , Paulus, Aneel , Chitta, Kasyapa S., Mohanty, Chitralekha, Gullbo, Joachim, Chanan‐Khan, Asher , Linder, Stig , Chitta, Kasyapa, Chanan-Khan, Asher, Wang, Xin , Caulfield, Thomas R , Paulus, Aneel

Chemical Biology & Drug Design | April 9, 2015 | Volume: 86 | Issue: 5 | Pages: 1036-1048

10.1111/cbdd.12571 | PMID 25854145 Get It

The ubiquitin–proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b‐AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure–activity relationship (SAR) study on b‐AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active‐site‐directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non‐proteasome DUBs, on recombinant kinases, or on caspase‐3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor.